Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nuvation Bio

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
From Nuvation Bio
Via Business Wire
Tickers NUVB
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Present at the Cantor Global Healthcare Conference
From Nuvation Bio
Via Business Wire
Tickers NUVB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.